Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response contains two on-topic claims: it generally describes Veregen as dermatologic and for external genital/perianal warts, which is supported. However, it omits key label qualifiers (immunocompetent status and age ≥18) and does not include labeled use limits (16 weeks) or important non-indicated sites/limitations, making overall alignment partial.
Category Scores
Accurate Statements
Veregen (sinecatechins) es un medicamento de uso dermatológico.
The provided label describes Veregen as a topical ointment for external genital and perianal warts (Section 1.1; dosage is topical in Section 2.1).
Veregen se indica para verrugas genitales externas por HPV.
Indicated for topical treatment of external genital warts (condylomata acuminata) (Section 1.1).
Unsupported Statements
Veregen se indica para verrugas genitales externas por HPV.
The label indication is for external genital and perianal warts (condylomata acuminata) in immunocompetent patients 18 years and older; the claim omits these required qualifiers (Section 1.1).
Contradictions
Important Omissions
Indication qualifier: immunocompetent patients 18 years and older.
Importance:
Moderate
Duration/use limits: treatment continued until complete clearance but no longer than 16 weeks; safety/effectiveness not established beyond 16 weeks or for multiple treatment courses.
Importance:
Moderate
Key limitations on non-indicated sites (e.g., not for urethral, intra-vaginal, cervical, rectal, or intra-anal disease) and avoidance on open wounds.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the core indication for external genital/perianal warts is supported, the claims omit immunocompetent/age criteria and key limitations (16-week maximum and non-indicated anatomic sites), which could lead to incomplete or potentially unsafe use if taken as full prescribing details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Missing required label qualifiers (immunocompetent status and age ≥18) and omission of key use limitations (≤16 weeks) and important site/condition exclusions.
Suggested Improvement
Revise the indication claim to: topical treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients ≥18 years, and include that treatment should not exceed 16 weeks and is not indicated for urethral/intra-vaginal/cervical/rectal/intra-anal disease or open wounds.